Rasmus Tetens Hoeg, M.D.
Associate Professor
To see if Rasmus Tetens Hoeg is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Specialties
Bone Marrow Transplant
Internal Medicine
Stem Cell Transplant
Malignant Hematology
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
Additional Numbers
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Hoeg believes in shared decision making. Most patients with blood cancers face many choices, some of them potentially life-altering. A choice may be whether to pursue an aggressive, dangerous treatment that may lead to cure versus an easier treatment that ensures a good quality of life but a shortened life span. Dr. Hoeg recognizes the difficulty in making such choices and encourages patients to bring family and close friends to the Cancer Center.
Clinical Interests
Dr. Hoeg specializes in the treatment of hematologic malignancies (cancers). Among other disease, he sees patients with acute and chronic leukemias, lymphoma and multiple myeloma.
Dr. Hoeg treats this cancers with chemotherapy, immune therapy and stem cell transplantations.
Research/Academic Interests
Dr. Hoeg participates in research across several hematologic cancers but his main focus is on improving the outcomes after allogeneneic stem cell transplantation.
Division
Malignant Hematology/Cellular Therapy and Transplantation
Center/Program Affiliation
Undergraduate School
B.A., History and English, University of Copenhagen, Copenhagen, Denmark 1998
Medical School
M.D., University of Copenhagen, Copenhaven, Denmark 2005
Residency
Internal Medicine, Gundersen Lutheran Medical Foundation, La Crosse WI 2008
Fellowship
Hematology, Herlev Hospital, Denmark, 2010-2011
Fellowship
Hematology/Oncology, Næstved Sygehus, Næstved, Denmark 2009-2010
Fellowship
Hematology/Oncology, Næstved Sygehus, Næstved, Denmark 2012-2013
To view a detailed list of Dr. Hoeg's publications, please click here.
https://ucdavis.pure.elsevier.com/en/persons/rasmus-hoeg/publications/
Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw. 2023 Feb;21(2):108-115. doi: 10.6004/jnccn.2023.0007. PMID: 36791762.
Othman T, Lowsky R, Richman C, Hoeg R, Abedi M, Tuscano J. Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma. Bone Marrow Transplant. 2023 Oct;58(10):1143-1145. doi: 10.1038/s41409-023-02025-0. Epub 2023 Jun 30. PMID: 37391654.
Tsao M, Hoeg R, Pecoraro J, Kuehner M, Deen B, Guglielmo J. Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide. J Oncol Pharm Pract. 2024 Aug 18;10781552241276418. doi: 10.1177/10781552241276418. Epub ahead of print. PMID: 39155604.
Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L. Impact of Prior Inotuzumab Ozogamicin Treatment on Brexucabtagene Autoleucel outcomes in Adults with B-cell ALL. Blood Adv. 2024 Aug; 2:bloodadvances.2024013747. doi: 10.1182/bloodadvances.2024013747. Epub ahead of print. PMID: 39093952.
Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 Aug;119:106885. doi: 10.1016/j.leukres.2022.106885. Epub 2022 Jun 8. PMID: 35738024.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 Jan;63(1):231-234. doi:10.1080/10428194.2021.1975190. Epub 2021 Sep 6. PMID:34486920.
Pham B, Hoeg R, Krishnan R, Richman C, Tuscano J, Abedi M. Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome. Bone Marrow Transplant. 2021 Sep 1;56:2975–2980. doi:10.1038/s41409-021-01444-1.
Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 Jul;21(7):e611-e618. doi:10.1016/j.clml.2021.02.007. Epub 2021 Mar 2. PMID:33811007.
Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 Apr 1;96(4):E114-E117. doi:10.1002/ajh.26105. Epub 2021 Feb 26. PMID:33476436.
Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021 Mar 11;11:649209. doi:10.3389/fonc.2021.649209. PMID:33777810.